Jaime Almandoz, MD, MBA

Almandoz challenged one of the most persistent misconceptions in metabolic disease management, that obesity treatment is primarily about weight loss, arguing instead that obesity is a systemic driver of healthcare utilization across multiple high-cost disease states including type 2 diabetes, cardiovascular disease, osteoarthritis, chronic kidney disease, and MASH, and that by the time a patient develops liver cirrhosis, heart failure, or end-stage kidney disease, the financial and human costs have already become enormous and largely preventable with earlier intervention.

Almandoz described his interpretation of the SYNCHRONIZE-1 findings, noting that while substantial and statistically significant weight reduction was observed, what captured his attention most was the nature and distribution of that weight loss, with the MRI sub-study demonstrating meaningful reductions in visceral and liver fat alongside relative preservation of lean mass, collectively pointing to a quality of weight loss that is biologically distinct from generalized weight loss.

Almandoz explained that while GLP-1 receptor agonism alone delivers meaningful benefits in appetite regulation, satiety, glycemic control, and cardiorenal and liver outcomes, the addition of glucagon receptor agonism introduces a distinct and complementary layer of biology that goes beyond weight loss alone to address the metabolic drivers most closely linked to insulin resistance, cardiometabolic risk, and MASH progression.

Jaime Almandoz characterized the historical management of metabolic disease as paradoxically siloed given how biologically integrated these conditions are, noting that a patient may have their obesity managed by one clinician, their diabetes by another, their cardiovascular disease by a third, and their liver disease, if addressed at all, evaluated in yet another separate setting, while the patient is experiencing all of these as one interconnected metabolic condition, creating fragmentation that delays diagnosis, duplicates effort, and leaves critical windows for intervention unaddressed.

Almandoz framed obesity, type 2 diabetes, cardiovascular disease, and MASH not as separate conditions but as different manifestations of the same underlying metabolic dysfunction, making MASH not merely a liver problem but a signal of broader cardiometabolic burden that demands comprehensive attention.

To truly shift the landscape in obesity care, explains Jaime Almandoz, MD, MBA, UT Southwestern, care models and policies must also consider quality of life and total health outcomes.

Jaime Almandoz, MD, MBA, of UT Southwestern Medical Center, speaks on results of a study that investigated tirzepatide uptake trends in commercial claims data.